An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer.

BACKGROUND: Although combining targeted agents with conventional, first-line cytotoxic therapy has improved survival outcomes in patients with advanced colorectal cancer, further improvements in outcomes and tolerability are needed. METHODS: This phase I study evaluated the feasibility of combining...

תיאור מלא

מידע ביבליוגרפי
Main Authors: Brady, J, Corrie, P, Chau, I, Digumarti, R, Adams, L, Botbyl, J, Laubscher, K, Midgley, R, Mallath, M
פורמט: Journal article
שפה:English
יצא לאור: 2013